We help biopharmaceutical leaders navigate a successful commercialization journey - the launch of their product and the company that supports it.
Click on a box below to explore the capabilities that we use to solve your business
problems and tranform the way your oganization functions.
We understand the commercialization process can be uncertain. We begin by clarifying your commercialization journey and providing de-risking strategies.
The onslaught of priorities, workstreams, and tasks is messy. We streamline this process and architect an integrated product and corporate launch plan.
Executing plans amid timeline and budget pressures can be intense. We build fit-for-purpose capabilities designed to ease these pain points and enable successful outcomes.
SVA Life Sciences consulted with the VP of Medical Affairs in a biopharmaceutical company during their clinical development phase to determine a process in which the organization could realize the benefit of improved collaboration between all sectors of the firm as it relates to competitive market intelligence. It was determined that in the early phases of development, the team lost too much time surveying the marketplace and the competitors within, as well as routing information around the organization via emails.
Read More
SVA Life Sciences was brought in by the VP of Sales Operations for a late biopharmaceutical company in the last three months prior to their PDUFA date. The VP was stretched thin, directing multiple projects all with the same due date! The sales representative credentialing program hadn’t been started and needed to still get done. Without it, their sales reps wouldn’t have access to the hospitals and institutions that were so vital to the success of the product and patients in need. He contacted SVA Life Sciences for help.
Read More
SVA Life Sciences began working with this U.S. based clinical-stage biopharmaceutical company upon their completed acquisition of four European biotech entities. They needed to translate the financial information of these acquired entities into a consolidated book of financial statements. They had also just completed their IPO requiring the need to report consolidated financial statements. Finally, the company decided to make some early moves in the process of transitioning from a clinical stage company to a commercial company by upgrading from QuickBooks to a financial platform. One that would adapt to their growing business needs and sophistication as well as be flexible enough to allow for long-term growth as the business matures.
Read More
SVA Life Sciences consulted with the VP of Medical Affairs in a biopharmaceutical company during their clinical development phase to determine a process in which the organization could realize the benefit of improved collaboration between all sectors of the firm as it relates to competitive market intelligence. It was determined that in the early phases of development, the team lost too much time surveying the marketplace and the competitors within, as well as routing information around the organization via emails.
Read More
